Juventas Therapeutics is a biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases. The company's lead product, Stromal-cell Derived Factor 1 (SDF-1), has been shown to protect and repair tissue following organ-damage in a broad range of pre-clinical disease models.
Juventas' first clinical target will be treatment of patients with advanced heart failure. The company has demonstrated that SDF-1 therapy has the potential to improve cardiac function following a heart attack by recruiting the body's own stem cells to the damaged region, the prevention of cardiac cell death and promotion of new blood vessel growth in the heart.
In addition to heart failure, Juventas is developing SDF-1 into a platform therapy with active development programs in peripheral vascular disease and wound healing.
Initial JumpStart Investment: June 2007
For more information on Juventas Therapeutics, contact: Lynn-Ann Gries